New Drug Development Pipeline

Biozipcode, Inc. has completed the basic research for the definitive cure treatment of diabetes and its complications in humans (repositioning). For these derivatives, we are proceeding with KIYAN MEDICAL Co., Ltd. as a candidate.

Furthermore, regarding repositioning, the development through repositioning allows for a potentially quicker progression to Phase 1 clinical trials, which confirm safety and pharmacokinetics in healthy adults, since the safety and pharmacokinetics in humans have already been established for the existing drug. This approach could significantly reduce the development period and costs, which are said to take over 10 years for new drugs.

Additionally, we are also advancing the development of a completely new cure for diabetes and its complications using Biozipcode technology (cell targeting technology).

Using a Biozipcode for diabetes stem cells to target existing HDAC inhibitors to these cells. Cell-Targeted Drugs: The ultimate new technology beyond molecular targeting.

Development of tissue regeneration materials that can integrate into tissues without the need for transplantation or sutures. This is a new regenerative therapy focused on healing skin damage, such as burns.

Selling companion diagnostics that determine diabetes based on the presence of diabetes stem cells in peripheral blood.

By utilizing a common Biozipcode for cancer, not only new drugs but also previously unusable drugs due to side effects can be reused.

Treatment method using the existing HDAC inhibitor ” HDAC inhibitor” + “Insulin.” By repositioning existing drugs, it is applied to patients with type 2 diabetes.

For details on our pipeline and research, please visit the KIYAN MEDICAL Corporation website.